Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations
29 2월 2024 - 9:30PM
Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a
clinical-stage TechBio company specializing in developing
AI-Immunology™ powered vaccines, today announces that it will host
a Research & Development (R&D) Day focusing on its core
AI-Immunology™ platform on March 19, 2024, at 14:00 - 18:00 CET /
8:00 a.m. - 12:00 a.m. EST.
The R&D Day will feature a series of talks
from Evaxion’s scientists and bioinformaticians, providing insights
into Evaxion’s validated AI-Immunology™ platform for vaccine target
discovery, design and development. The event will highlight the
unique predictive capabilities that differentiate the platform and
how these can help address severe unmet medical needs for patients
with cancer and infectious diseases.
The event will take place at Evaxion’s
facilities in Hørsholm, Denmark, and will also be accessible via
live webcast. To attend the event, please register using the
following link.
A replay of the presentations will be available
on our website following the event.
About AI-Immunology™
AI-Immunology™ is a scalable and adaptable
artificial intelligence technology platform at the forefront of
vaccine discovery for infectious diseases and cancers. By
integrating the collective power of proprietary AI models PIONEER™,
EDEN™, RAVEN™, and ObsERV™, the platform can model the complexity
of the patient’s immune system. AI-Immunology™ advanced
computational modeling swiftly and uniquely identifies, predicts,
and designs vaccine candidates, revolutionizing the landscape of
immunotherapy by offering a holistic and personalized approach to
combat fast-evolving pathogens and malignant cells.
About EVAXION
Evaxion Biotech A/S is a pioneering TechBio
company based upon its AI platform, AI-Immunology™. Evaxion’s
proprietary and scalable AI prediction models harness the power of
artificial intelligence to decode the human immune system and
develop novel immunotherapies for cancer, bacterial diseases, and
viral infections. Based upon AI-Immunology™, Evaxion has developed
a clinical-stage oncology pipeline of novel personalized vaccines
and a preclinical infectious disease pipeline in bacterial and
viral diseases with high unmet medical needs. Evaxion is committed
to transforming patients’ lives by providing innovative and
targeted treatment options. For more information about Evaxion and
its groundbreaking AI-Immunology™ platform and vaccine pipeline,
please visit our website.
Forward-Looking
Statement
This announcement contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. The words “target,” “believe,” “expect,”
“hope,” “aim,” “intend,” “may,” “might,” “anticipate,”
“contemplate,” “continue,” “estimate,” “plan,” “potential,”
“predict,” “project,” “will,” “can have,” “likely,” “should,”
“would,” “could,” and other words and terms of similar
meaning identify forward-looking statements. Actual results may
differ materially from those indicated by such forward-looking
statements as a result of various factors, including, but not
limited to, risks related to: our financial condition and need for
additional capital; our development work; cost and success of our
product development activities and preclinical and clinical trials;
commercializing any approved pharmaceutical product developed using
our AI platform technology, including the rate and degree of market
acceptance of our product candidates; our dependence on third
parties including for conduct of clinical testing and product
manufacture; our inability to enter into partnerships; government
regulation; protection of our intellectual property rights;
employee matters and managing growth; our ADSs and ordinary
shares, the impact of international economic, political, legal,
compliance, social and business factors, including inflation, and
the effects on our business from the worldwide ongoing COVID-19
pandemic and the ongoing conflict in the region
surrounding Ukraine and Russia and the Middle East; and other
uncertainties affecting our business operations and financial
condition. For a further discussion of these risks, please refer to
the risk factors included in our most recent Annual Report on Form
20-F and other filings with the U.S. Securities and Exchange
Commission (SEC), which are available
at www.sec.gov. We do not assume any obligation to
update any forward-looking statements except as required by
law.
Contact Information
Evaxion Biotech A/S
Christian Kanstrup
Chief Executive Officer
cka@evaxion-biotech.com
Source: Evaxion Biotech
Evaxion Biotech AS (NASDAQ:EVAX)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Evaxion Biotech AS (NASDAQ:EVAX)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024